Embera NeuroTherapeutics, Inc.
BioSpace1, 2031 Kings Highway
Shreveport, LA 71103
BioSpace1, 2031 Kings Highway
Shreveport, LA 71103
Embera Management Team
Embera Board of Directors
Scientific Advisory Board
- Kathleen Brady, MD, Ph.D.
- George Koob, Ph.D.
- Bruce McCarthy, MD
- Charles O'Brien, MD, Ph.D.
- Rajita Sinha, Ph.D.
Investors
Robert B. Linke - President and Chief Executive Officer, Director
Mr. Linke has over twenty-five years of diversified healthcare experience in pharma/biopharmaceutical, medical device, diagnostic, and healthcare informatics markets. His healthcare experience includes leadership roles developing and commercializing products at both public companies, Baxter International and Caremark International, and private equity-backed companies, including Periodontix, a biotech company, and Rapid Micro Biosystems, a diagnostic company, raising over $35 million in private equity to fund these companies.
Nicholas E. Goeders, Ph.D. - Chief Scientific Officer, Director
Dr. Goeders is a founder of the Company and internationally recognized leader in addiction research that includes over 25 years of NIH-funded research that led to the discovery of EMB-001. He is currently the Head of the Department of Pharmacology, Toxicology & Neuroscience at the Louisiana State University Health Sciences Center in Shreveport, Louisiana.
Barbara S. Fox, Ph.D. – Vice President, Research and Development
Dr. Fox leads Embera’s research and development efforts on a consulting basis, leveraging her broad background in addiction R&D. This experience includes VP Discovery Research of ImmuLogic Pharmaceutical Corp. where she led their cocaine vaccine development program and Recovery Pharmaceuticals, as founder, President and CSO, developing and marketing medications for the treatment of addiction including nicotine dependence products.
Carol Gloff, Ph.D. – Vice President, Regulatory Affairs
Dr. Gloff directs Embera’s regulatory efforts including all IND enabling studies. She is an experienced regulatory consultant working with a range of development stage pharmaceutical and biotech companies from IND filing through FDA approval that includes a drug combination. Dr. Gloff is the former VP of Regulatory Affairs for Alkermes and ImmunoGen.
Michael Short, Vice President, Business Strategy and Development
Mr. Short brings significant experience to Embera’s business development efforts on a consulting basis, leveraging upon licensing deals completed with the top 20 pharmaceutical companies and more than $20 million raised in venture capital. Recent roles include President and VP Strategy and Business Development at BaroFold Inc, CEO at GlycoForm Ltd and founder CEO at RioTech Pharmaceuticals Ltd.